Perrigo shares dip, breaking three-day gain streak
NEW YORK - Perrigo Co . (NYSE:PRGO) saw its shares decline by 1.43% to close at $30.91 on Tuesday, halting a three-day run of advances. The pharmaceutical company's stock is currently...
Strong Buy
or
Abbott Labs News & Analysis
-
-
Edwards Lifesciences stock dips, ending four-day rally as market declines
NEW YORK - Edwards Lifesciences (NYSE:EW), a prominent player in the medical devices sector, saw its shares decline by 0.48% to close at $68.85 today, halting a four-day streak of gains amid...
-
Diabetes drugs like Ozempic boost glucose monitor sales
Amid rising concerns that advanced diabetic treatments could reduce the need for blood glucose monitoring devices, recent financial reports indicate a contrasting trend. Companies such as...
-
Bristol Myers Squibb shares dip as market shows mixed results
NEW YORK - Bristol Myers (NYSE:BMY) Squibb Co. (NYSE:BMY) experienced a downturn on Thursday, ending a two-day streak of gains as its shares dropped 1.42% to close at $50.84. The decline...
-
Medical Devise Stocks Gain on Better Than Feared Wegovy Data
(Updated - November 13, 2023 2:32 PM EST) Penumbra, Inc. (NYSE:PEN) and other medical device stocks gained on Monday. The move higher was tied to new Wegovy data from Novo Nordisk...
-
Institutional investors hold sway over Abbott Laboratories stock
Institutional investors continue to exercise significant influence over Abbott Laboratories (NYSE:ABT) due to their substantial ownership of approximately 76% of the company's shares,...
-
Abbott Granted FDA Approval of HPV Test to Run on Alinity m
Abbott (ABT) has received U.S. Food and Drug Administration (FDA) approval for its molecular human papillomavirus or HPV screening solution, adding a powerful cancer screening tool for...
-
Pfizer shares see slight rise amid positive market trends
Pfizer Inc. (NYSE:PFE)'s shares experienced a marginal increase of 0.03% to $30.56 on Tuesday, marking the second day of consecutive gains in a favorable market environment. The S&P...
-
Abbott raises earnings outlook after surpassing Q3 estimates
Abbott has raised its earnings outlook for the full year 2023 to between $4.42 and $4.46 per share, up from the previous range of $4.30 and $4.40, after reporting Q3 revenues of $10.1...
-
Abbott’s Minimally Invasive Devices Show Promising Results In Heart Valve Trials
Abbott Laboratories (NYSE:ABT) recently presented successful trial data for its minimally invasive devices, TriClip and MitraClip G4, at the 35th TCT annual scientific symposium. The...
-
Morgan Stanley maintains Abbott Labs at 'equalweight' with a price target of $107.00
An analyst from Morgan Stanley maintained Abbott Labs (NYSE: ABT) at 'equalweight' with a price target of $107.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
UBS maintains Abbott Labs at 'buy' with a price target of $122.00
An analyst from UBS maintained Abbott Labs (NYSE: ABT) at 'buy' with a price target of $122.00 from a prior price target of %currency%%price%. Prior to this rating, Abbott Labs had 18 buy...
-
Raymond James maintains Abbott Labs at 'outperform' with a price target of $110.00
An analyst from Raymond James maintained Abbott Labs (NYSE: ABT) at 'outperform' with a price target of $110.00 from a prior price target of %currency%%price%. Prior to this rating, Abbott...
-
Barclays maintains Abbott Labs at 'overweight' with a price target of $133.00
An analyst from Barclays maintained Abbott Labs (NYSE: ABT) at 'overweight' with a price target of $133.00 from a prior price target of %currency%%price%. Prior to this rating, Abbott Labs...
-
Earnings call: Abbott's Q3 Earnings Beat Expectations, Raises Full-Year Guidance Amid Strong Business Growth
Abbott Laboratories (NYSE:ABT) reported robust third-quarter earnings in 2023, outperforming expectations with an adjusted earnings per share (EPS) of $1.14. The company also raised its...
-
Stifel maintains Abbott Labs at 'buy' with a price target of $115.00
An analyst from Stifel maintained Abbott Labs (NYSE: ABT) at 'buy' with a price target of $115.00 from a prior price target of %currency%%price%. Prior to this rating, Abbott Labs had 17...
-
Abbott Labs Q3 profits steady; raises midpoint of adjusted earnings outlook
Abbott Laboratories (NYSE:ABT) reported stable third quarter profits on Wednesday, with earnings of $1.44 billion or 82 cents per share. The adjusted earnings, which came in at $1.14 per...
-
Abbott gains as 'strong' performance tops Q3 expectations
Abbott (NYSE:ABT) shares are up more than 2% premarket Wednesday after the company reported earnings, topping consensus expectations. The medical device company {{erl-8192||reported Q3 EPS...
-
Abbott Labs earnings beat by $0.04, revenue topped estimates
Investing.com - Abbott Labs (NYSE: ABT) reported third quarter EPS of $1.14, $0.04 better than the analyst estimate of $1.10. Revenue for the quarter came in at $10.1B versus the consensus...
-
Mizuho Securities maintains Abbott Labs at 'neutral' with a price target of $105.00
An analyst from Mizuho Securities maintained Abbott Labs (NYSE: ABT) at 'neutral' with a price target of $105.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
UBS maintains Abbott Labs at 'buy' with a price target of $118.00
An analyst from UBS maintained Abbott Labs (NYSE: ABT) at 'buy' with a price target of $118.00 from a prior price target of %currency%%price%. Prior to this rating, Abbott Labs had 15 buy...
-
Abbott Laboratories Explores Consumer Wearables Market As COVID Testing Sales Dwindle: CEO
Abbott Laboratories (NYSE: ABT) CEO Robert Ford, while speaking at the HLTH conference in Las Vegas, outlined the company's strategic move into the consumer wearables market. While Abbott...
-
Abbott Laboratories, American Financial Group, and Bank OZK to trade ex-dividend
Abbott Laboratories (NYSE:ABT), American Financial Group Inc (NYSE:AFG), and Bank OZK (NASDAQ:OZK) are scheduled to trade ex-dividend on Thursday, October 12, 2023. This comes as...
-
3 Medical Product Stocks With Solid Dividend Yield: ABT & Others
Owing to the rising market volatility, it would be a wise decision to focus on some dividend-paying companies like these.
-
Jefferies maintains Abbott Labs at 'hold' with a price target of $112.00
An analyst from Jefferies maintained Abbott Labs (NYSE: ABT) at 'hold' with a price target of $112.00 from a prior price target of %currency%%price%. Prior to this rating, Abbott Labs had...
-
Abbott Declares $0.51 Quarterly Dividend; 2% Yield
Abbott (ABT) declared a quarterly dividend of $0.51 per share, or $2.04 annualized.The dividend will be payable on November 15, 2023, to stockholders of record on October 13, 2023, with an...
-
Abbott Laboratories exhibits robust financial health despite recent share price dip
Despite a 7.0% drop in its share price over the past month, Abbott Laboratories (NYSE:ABT) is showing signs of strong financial health that could potentially lead to an increase in its...
-
Barclays maintains Abbott Labs at 'overweight' with a price target of $132.00
An analyst from Barclays maintained Abbott Labs (NYSE: ABT) at 'overweight' with a price target of $132.00 from a prior price target of %currency%%price%. Prior to this rating, Abbott Labs...
-
Wolfe Research now neutral on Abbott as short view becomes trickier
Abbott Laboratories (NYSE:ABT) was lifted to Peer Perform from Underperform at Wolfe Research on Friday, with the firm removing its price target for the stock. Analysts told investors in...
-
Mizuho Securities maintains Abbott Labs at 'neutral' with a price target of $115.00
An analyst from Mizuho Securities maintained Abbott Labs (NYSE: ABT) at 'neutral' with a price target of $115.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
BTIG maintains Abbott Labs at 'buy' with a price target of $131.00
An analyst from BTIG maintained Abbott Labs (NYSE: ABT) at 'buy' with a price target of $131.00 from a prior price target of %currency%%price%. Prior to this rating, Abbott Labs had 17 buy...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
